Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study. (23rd December 2020)

• Record Type: Journal Article
• Authors: Komeda, Takuji; Takazono, Takahiro; Hosogaya, Naoki; Miyazaki, Taiga; Ogura, Eriko; Iwata, Shinpei; Miyauchi, Hideyuki; Honda, Keiichi; Fujiwara, Masakazu; Ajisawa, Yoshikazu; Watanabe, Hideaki; Kitanishi, Yoshitake; Hara, Kanae; Mukae, Hiroshi
• Is Part Of: Clinical infectious diseases. Volume 73:Number 5(2021)
• Page Start: e1181
• Page End: e1190
• Publication Date: 2020-12-23
• Subjects: baloxavir -- human influenza -- hospitalization -- Japan -- neuraminidase inhibitor; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1870
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Baloxavir marboxil (baloxavir) is a single-dose, oral antiinfluenza drug with a novel mechanism of action. We compared the incidence of hospitalization in patients treated with baloxavir vs neuraminidase inhibitors. Methods: In this retrospective, observational, cohort study, we used real-world patient data extracted from a Japanese health insurance claims database. The enrollment period was 1 October 2018 to 17 April 2019. On day 1, eligible patients (N = 339 007) received baloxavir, oseltamivir, zanamivir, or laninamivir. Baseline characteristics were standardized using the inverse probability of treatment weighting method. The primary end point was the incidence of hospitalization (days 2–14). Secondary end points included antibacterial use, secondary pneumonia, and additional antiinfluenza drug use. Results: Compared with the baloxavir group, the incidence of hospitalization was greater in the oseltamivir group (risk ratio [RR] and 95% confidence interval [CI], 1.41 [1.00–2.00]; risk difference [RD] and 95% CI, 0.06 [.01–.12]) and zanamivir group (RR, 1.85 [1.23–2.78]; RD, 0.11 [.02–.20]). Oseltamivir-treated patients were less likely to require antibacterials than baloxavir-treated patients (RR, 0.87 [.82–.91]). However, oseltamivir-treated patients were more likely to be hospitalized with antibacterials (RR, 1.70 [1.21–2.38]) or antibacterial injection (RR, 1.67 [1.17–2.38]) than baloxavir-treated patients (post hoc analysis). Compared with baloxavir-treated patients, additional antiinfluenza drug use was greater in oseltamivir-, zanamivir-, and laninamivir-treated patients (RR, 1.51 [1.05–2.18], 2.84 [2.04–3.96], and 1.68 [1.35–2.10], respectively). Conclusions: Baloxavir is an efficacious antiinfluenza treatment that may reduce hospitalization compared with oseltamivir and zanamivir. Clinical Trials Registration: University hospital Medical Information Network Clinical Trials Registry (UMIN000038159). Abstract : Baloxavir marboxil is a single-dose oral antiinfluenza drug with a novel mechanism of action. This real-world data study indicates that baloxavir marboxil may reduce hospitalization after influenza outpatient treatment compared with neuraminidase inhibitor treatment.